Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an observational prospective study. The aim is to assess the prevalence of test positivity (swab or serological examination) to Coronavirus Disease-2019 (Covid-19) in relation to the duties and related occupational risk.
The study protocol provides for a collection of basic data relating to all hospital workers who voluntarily underwent the test (age, sex, type of occupation - doctor / nurse / socio-health / administrative operator; attendance in Covid-19 wards department), IgG outcome (quantitative level) and swab outcome (negative, weakly positive, positive).
The cohort of hospital workers constitutes a population of particular relevance for the development of appropriate strategies for the surveillance of hospital risk for SARS-CoV-2 infection (relationship to the type of job, clinical evolution) and the available data are very limited.
The asymptomatic staff cohort constitutes the ideal population context to contribute to knowledge of aspects of the spread of the virus.
The limitations of current serological tests are well known, which do not allow to distinguish the acute phase of the infection and therefore the persistence of contagiousness. Similarly, the genomic characteristics of the SARS-CoV-2 virus are not known in asymptomatic but swab positive subjects compared to the virus isolated from symptomatic patients.
In the cohort of operators who tested positive for nasopharyngeal swab (both symptomatic and asymptomatic), the availability of serological tests will allow to evaluate the antibody response over time in relation to the clinical evolution of the infection, and the persistence of a protective titer over time.
Methods and study design
The cohort of symptomatic hospital workers who tested positive for the swab includes 250 operators. The cohort will be evaluated as a prospective epidemiological study;
The cohort of asymptomatic / paucisymptomatic operators will include the cohort of operators who will test positive in the serological analysis. From the entire population of hospital workers (over 3000), three controls will be identified for each operator who tested positive for the serological test on the same day and are negative for the serological test. Considering the positive percentage of 5.5% in the serological survey (from the first epidemiological data reported at the ASST of Monza), the positive screening cohort and the control cohort of about 480 are estimated at about 160.
The serological test that will be used is the one required by the indication of the Circular G1.2020.00117959 of 22 April 2020. It is a test with the CLIA method designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS virus "spike" protein -CoV-2, selected for its ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses.
The product has been designed to meet the need to identify in the population those who have already been infected with the virus, whose diagnosis has not been made through the execution of a swab and a molecular diagnostic test.
The questionnaire will be administered to all operators.
Data anonymization Health worker will be identified with an 8-digit code followed by the letters OS and the year of collection (e.g. 00000001 OS / 2020); in biological sampling the laboratory will identify the patient with the same code and that will be the linkage code between the database and the bio-bank because it is unique for each worker at the ASST in Monza.
Biological studies
The fields of research in the biological field that the protocol aims to pursue are listed below:
Statistic analysis Central tendency and dispersion measures will be used for descriptive analyzes. The percentage of positive subjects (serological and / swab) will be calculated as the number of positive subjects on the total number of participating subjects. The percentage of immune subjects will be calculated as the number of subjects with IgG immunoglobulins out of the total number of participants.These percentages will also be calculated for age and sex groups and for each characteristic considered relevant.
The logistic regression model will be used to identify demographic / social variables of predisposition to positivity.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The asymptomatic medical staff cohort | The cohort of asymptomatic / paucisymptomatic operators will include the cohort of operators who will test positive in the serological analysis. From the entire population of hospital workers (over 3000), three controls will be identified for each operator who tested positive for the serological test that were analyzed on the same day and were negative for the serological test. |
| |
| The symptomatic medical staff cohort | The cohort of symptomatic hospital workers who tested positive for the swab includes 250 operators. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Investigation of the prevalence of test positivity | Other | The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk. It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus "spike" protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses . |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of test positivity | Desciption of the prevalence of test positivity (swab or serological examination) in relation to the duties and related occupational risk | Until the end of the study (approximately 6 months). |
| Correlation of the positive result of the test with the manifestations of the signs | Description of the positive result of the test (swab or serological examination) with the manifestations of the signs / symptoms collected in the previous months from the attached form in the cohort of positive cases and related negative controls. | Until the end of the study (approximately 6 months). |
| Development of COVID | Description of the outcome of positive serological and swab test operators in terms of development of COVID-related symptomatology | Until the end of the study (approximately 6 months). |
| Measure | Description | Time Frame |
|---|---|---|
| Analysis of genomic sequences of the virus | to correlate the virus genomic sequence of asymptomatic but positive serological and swab operators with the available data of the SARS-CoV-2 virus sequences. | Until the end of the study (approximately 6 months). |
| Evaluation of the test relevance |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Failure to consent to serological screening or failure to consent to study participation (there are two different consent)
Not provided
Not provided
Not provided
The study population consists of:
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ASST Monza-Ospedale San Gerardo | Monza | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32091533 | Background | Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available. | |
| 32333843 | Background |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D018352 | Coronavirus Infections |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
serological samples and nasopharyngeal swab
|
Evaluate the relevance of tests with greater sensitivity and specificity in the population negative for the throat swab but positive for the serological investigation; |
| Until the end of the study (approximately 6 months). |
| Evaluation of predictive biomolecular markers | Evaluation biomolecular markers that are predictive of susceptibility to infection and predictive of symptomatic infection | Until the end of the study (approximately 6 months). |
| The trend over time of the antibody response in subjects positive | Evaluate the trend over time of the antibody response in subjects positive to the serological test and to the swab (both symptomatic and asymptomatic). | Until the end of the study (approximately 6 months). |
| The frequency of re-infection | Evaluate the frequency of re-infection (symptomatology compatible with COVID and positive swab) in operators who tested positive for serological and swab tests. | Until the end of the study (approximately 6 months). |
| Evaluation of the mode of transmission relatively anamnestic data | Evaluate the mode of transmission between relatives by collecting anamnestic data. | Until the end of the study (approximately 6 months). |
| The relation between mode of transmission and the available clinical documentation | Assess the mode of transmission between relatives by collecting the available clinical documentation | Until the end of the study (approximately 6 months). |
| Evaluation of the mode of transmission for the use of barriers | Evaluate the mode of transmission between relatives by collecting the barriers used in the home: none, mask and spacing, voluntary isolation. | Until the end of the study (approximately 6 months). |
| Hunter E, Price DA, Murphy E, Schim van der Loeff I, Baker KF, Lendrem D, Lendrem C, Schmid ML, Pareja-Cebrian L, Welch A, Payne BAI, Duncan CJA. First experience of COVID-19 screening of health-care workers in England. Lancet. 2020 May 2;395(10234):e77-e78. doi: 10.1016/S0140-6736(20)30970-3. Epub 2020 Apr 22. No abstract available. |
| 32374370 | Background | Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020 Jun 9;323(22):2249-2251. doi: 10.1001/jama.2020.8259. No abstract available. |
| 31525455 | Background | Civra A, Colzani M, Cagno V, Francese R, Leoni V, Aldini G, Lembo D, Poli G. Modulation of cell proteome by 25-hydroxycholesterol and 27-hydroxycholesterol: A link between cholesterol metabolism and antiviral defense. Free Radic Biol Med. 2020 Mar;149:30-36. doi: 10.1016/j.freeradbiomed.2019.08.031. Epub 2019 Sep 13. |
| D014777 |
| Virus Diseases |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |